Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Preventative effects of anastrozole in post-menopausal women who are at high-risk for developing breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.12.19
Views: 371

Prof Jack Cuzick - Queen Mary University of London, London, UK

Prof Jack Cuzick speaks to ecancer at the 2019 San Antonio Breast Cancer Symposium about the preventative effects of anastrozole in post-menopausal, high-risk women.

He explains the rationale behind this study, which has achieved a 60 percent reduction of breast cancer incidence in the first five years and an additional 36 percent after every subsequent year.

Prof Cuzick also notes that this long-term follow up shows the effectiveness of anastrozole over tamoxifen.

He also discusses how patients were stratified as "high-risk", associated adverse effects and the possibility of investigating mortality in the future.

Watch the press conference here.

Read more about the study here

Related videos

follow us

WIN 2020

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation